Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study.

Shufelt CL, Merz CN, Prentice RL, Pettinger MB, Rossouw JE, Aroda VR, Kaunitz AM, Lakshminarayan K, Martin LW, Phillips LS, Manson JE.

Menopause. 2014 Mar;21(3):260-6. doi: 10.1097/GME.0b013e31829a64f9.

2.

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB.

JAMA. 2013 Oct 2;310(13):1353-68. doi: 10.1001/jama.2013.278040.

3.

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.

LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J; WHI Investigators.

JAMA. 2011 Apr 6;305(13):1305-14. doi: 10.1001/jama.2011.382.

4.

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee.

JAMA. 2004 Apr 14;291(14):1701-12.

PMID:
15082697
5.

Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials.

Wild RA, Wu C, Curb JD, Martin LW, Phillips L, Stefanick M, Trevisan M, Manson JE.

Menopause. 2013 Mar;20(3):254-60. doi: 10.1097/GME.0b013e31826f80e0.

6.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators.

JAMA. 2002 Jul 17;288(3):321-33.

PMID:
12117397
7.
8.

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML.

JAMA. 2007 Apr 4;297(13):1465-77. Erratum in: JAMA. 2008 Mar 26;299(12):1426.

PMID:
17405972
9.

Hormone therapy in menopause: An update on cardiovascular disease considerations.

Hale GE, Shufelt CL.

Trends Cardiovasc Med. 2015 Aug;25(6):540-9. doi: 10.1016/j.tcm.2015.01.008. Epub 2015 Feb 12. Review.

PMID:
26270318
10.

Transdermal hormone therapy and the risk of stroke and venous thrombosis.

Speroff L.

Climacteric. 2010 Oct;13(5):429-32. doi: 10.3109/13697137.2010.507111.

PMID:
20670199
11.

A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.

Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ.

Ann Intern Med. 2000 Dec 19;133(12):933-41.

PMID:
11119394
12.

Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen.

Modena MG, Bursi F, Fantini G, Cagnacci A, Carbonieri A, Fortuna A, Rossi R.

Am J Med. 2002 Sep;113(4):331-4. No abstract available.

PMID:
12361820
13.
14.

Different effects of oral conjugated equine estrogens and transdermal estrogen on undercarboxylated osteocalcin concentration in postmenopausal women.

Yasui T, Uemura H, Tomita J, Umino Y, Yamada M, Kuwahara A, Matsuzaki T, Maegawa M, Miura M, Irahara M.

Menopause. 2006 Jul-Aug;13(4):651-9.

PMID:
16837887
15.

Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy.

Grodstein F, Manson JE, Stampfer MJ, Rexrode K.

Arch Intern Med. 2008 Apr 28;168(8):861-6. doi: 10.1001/archinte.168.8.861.

16.

[Basic principles of hormone replacement therapy in the postmenopause].

Dören M.

Ther Umsch. 2000 Oct;57(10):628-34. Review. German.

PMID:
11081374
18.

Effects of different hormone therapies on breast pain in recently postmenopausal women: findings from the Mayo Clinic KEEPS breast pain ancillary study.

Files JA, Miller VM, Cha SS, Pruthi S.

J Womens Health (Larchmt). 2014 Oct;23(10):801-5. doi: 10.1089/jwh.2014.4871. Epub 2014 Sep 30.

19.

Vaginal estradiol use and the risk for cardiovascular mortality.

Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O.

Hum Reprod. 2016 Apr;31(4):804-9. doi: 10.1093/humrep/dew014. Epub 2016 Feb 13.

PMID:
26874358
20.

Menopause and stroke and the effects of hormonal therapy.

Lobo RA.

Climacteric. 2007 Oct;10 Suppl 2:27-31. Review.

PMID:
17882669

Supplemental Content

Support Center